# Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

> **NCT02388490** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 25 (actual)

## Conditions studied

- Relapsed or Refractory EBV-and CD30-positive Lymphomas

## Interventions

- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT02388490
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-25
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-04-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388490, "Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02388490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*